Sidekick Health acquires PINK! to bolster its femtech offering

The move allows Sidekick to integrate PINK!’s breast cancer prescription digital therapeutic into their portfolio.
Sidekick Health acquires PINK! to bolster its femtech offering

Healthtech Sidekick Health has acquired PINK!, a digital health company specialising in cancer support and women’s health. This strengthens its position in the digital therapeutics market. Terms are undisclosed. The teams will be combined.

This acquisition brings with it PINK! Coach, the only permanently listed prescription digital therapeutic (PDT) for breast cancer within Germany’s regulated nationwide DiGA (Digitale Gesundheitsanwendungen) formulary. PINK! Coach is a digital application developed to enhance health-related quality of life and health literacy, while also addressing the psychological, psychosomatic, and physical effects of breast cancer. PINK! Coach focuses on gradually and sustainably changing the user's health-related behaviours.

Sidekick Health’s acquisition will broaden the range of digital therapeutics it can offer to patients and to healthcare and life sciences companies in the US and EU. 

Sidekick has been growing at an 80% compound annual growth rate and currently works with five of the world's twenty largest healthcare companies to reshape the digital health landscape. Its products are prescribed on a regular basis by over 13,000 physicians. Within the US payer landscape, the company is notably collaborating with one of the largest health insurers, and is live with partners in Medicare, Medicaid and employer populations across the country. In the pharmaceutical sector, it has cultivated strategic partnerships with industry giants like Eli Lilly and Pfizer, with multiple partnerships across the US and Europe.

Dr. Tryggvi Thorgeirsson, Co-founder and CEO of Sidekick Health, commented on the acquisition: “The acquisition of PINK! aligns perfectly with our mission to transform healthcare globally through digital innovation. By integrating PINK!’s cutting-edge breast cancer prescription digital therapeutic into our portfolio, we are ready to offer an even more comprehensive portfolio of digital therapeutics to patients – including further expansion opportunities within women’s health and oncology. 

We are particularly excited to work with Prof. Dr. Pia Wülfing and her impressive team, whose dedication and expertise in breast cancer support and women’s health have been truly inspirational. Pia’s leadership at PINK! has created a strong foundation that we are eager to build upon.”

Prof. Dr. Pia Wülfing, founder and CEO of PINK!, shared: “Joining forces with Sidekick Health represents an exciting new chapter for PINK!. Together, we can leverage our combined expertise to make a profound impact on the lives of patients with breast cancer in Europe, North America, and beyond. This step will enable us to expand the reach of our digital health solutions, including with Sidekick’s partners, and continue to offer patients innovative solutions, providing better support and care for people living with cancer.”

Follow the developments in the technology world. What would you like us to deliver to you?
Your subscription registration has been successfully created.